Reply to ‘Sudden Cardiac Death Following Use of the Synthetic Cannabinoid MDMB-CHMICA’
Open Access
- 27 January 2016
- journal article
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 40 (3) , 240-242
Abstract
In a letter to the editor, Westin et al. described a case of sudden cardiac arrest after the consumption of a brown powder containing MDMB-CHMICA (methyl-(S)-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate) ( 1). In this case, 1.4 ng/mL MDMB-CHMICA was detected in the serum sample obtained 2 h postconsumption and the intake of this synthetic cannabinoid was assumed as the most probable cause of death by the authors. MDMB-CHMICA seems to be an extremely potent drug mediating its effects via agonist activity at the CB1 receptor of the endocannabinoid system ( 2). Since December 2014, numerous nonfatal and fatal intoxication cases involving this compound have been reported ( 3). Given the high prevalence and the limited data published in the scientific literature so far we would like to add some more data on MDMB-CHMICA serum concentrations encountered in forensic case work. It has to be noted that the semisystematic nomenclature used by producers and retailers of synthetic drugs may lead to confusion regarding the exact chemical structures. MDMB-CHMICA is often offered on the Internet under the name ‘MMB-CHMINACA’, which falsely implies an indazole core structure. Since its first appearance as a pure powder in an online shop selling research chemicals in September 2014, we have encountered this compound as an additive in 81 different brands of herbal mixtures during product monitoring activities in the frame of the EU-projects ‘Spice II Plus’ (JUST/2011/DPIP/AG/3597) and ‘Spice profiling’ (JUST/2013/ISEC/DRUGS/AG/6421). In our routine forensic analysis, we use a validated method currently detecting 94 synthetic cannabinoids in serum. Samples undergo a liquid–liquid extraction with hexane/ethyl acetate followed by analysis with a QTRAP® 4000 tandem mass spectrometer (Sciex, Darmstadt, Germany) in scheduled MRM mode with at least two ion transitions for each analyte. In the period of September 2014 to August 2015, we detected MDMB-CHMICA in 140 serum samples with this method (total number of samples analyzed for synthetic cannabinoids in this period: 1,046). In 30 of the cases, only trace amounts (<0.10 ng/mL) of MDMB-CHMICA were detected. The MDMB-CHMICA concentrations in the other 110 samples ranged from 0.10 to 91 ng/mL (median: 0.67 ng/mL, mean: 3.5 ng/mL). Among these were seven cases involving uptake of MDMB-CHMICA, for which comprehensive toxicological screening analyses were carried out (Table I). In five of the serum samples, no additional synthetic cannabinoids or other drugs were detected. In two of the samples, a second synthetic cannabinoid was detected in the serum sample (Figure 1). The highest concentration of MDMB-CHMICA (91 ng/mL) was determined in the serum sample of a 32-year-old man (Case #1), who was arrested because of selling herbal blends containing synthetic cannabinoids. In this case, 3,4-methylenedioxymethamphetamine (MDMA) (150 ng/mL) and 3,4-methylenedioxyamphetamine (MDA) (16 ng/mL) were also detected in the serum sample. The lowest concentration (<0.1 ng/mL) was detected in the serum sample of a 15-year-old boy who was offered a cigarette for smoking. After smoking, he started to vomit and became unresponsive. He was transferred to a pediatric clinic.Keywords
Funding Information
- Drug Prevention and Information Programme (JUST/2011/DPIP/AG/3597, JUST/2013/ISEC/DRUGS/AG/6421)
This publication has 10 references indexed in Scilit:
- Sudden Cardiac Death Following Use of the Synthetic Cannabinoid MDMB-CHMICAJournal of Analytical Toxicology, 2015
- Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ9-THC: Mechanism underlying greater toxicity?Life Sciences, 2014
- Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptorsToxicology and Applied Pharmacology, 2013
- Acute intoxication by synthetic cannabinoids – Four case reportsDrug Testing and Analysis, 2013
- Cytochrome P450-Mediated Oxidative Metabolism of Abused Synthetic Cannabinoids Found in K2/Spice: Identification of Novel Cannabinoid Receptor LigandsDrug Metabolism and Disposition, 2012
- Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findingsAddiction, 2012
- Apparent Inverse Relationship between Cannabinoid Agonist Efficacy and Tolerance/Cross-Tolerance Produced by Δ9-Tetrahydrocannabinol Treatment in Rhesus MonkeysThe Journal of Pharmacology and Experimental Therapeutics, 2012
- The effect of the postmortem interval on the redistribution of drugs: a comparison of mortuary admission and autopsy blood specimensForensic Science, Medicine and Pathology, 2012
- Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activityBiochemical Pharmacology, 2012
- Phase I Hydroxylated Metabolites of the K2 Synthetic Cannabinoid JWH-018 Retain In Vitro and In Vivo Cannabinoid 1 Receptor Affinity and ActivityPLOS ONE, 2011